Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Everolimus as Treatment After Embolization or Chemoembolization for Liver Metastases From Digestive Endocrine Tumors

Next Previous
X
Search
Trial Profile

Everolimus as Treatment After Embolization or Chemoembolization for Liver Metastases From Digestive Endocrine Tumors

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 11 Aug 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Everolimus (Primary) ; Doxorubicin; Ethiodized oil; Streptozocin
  • Indications Bone metastases; Cancer metastases; Colon cancer; Gastric cancer; Intestinal cancer; Liver metastases; Neuroendocrine tumours; Rectal cancer
  • Focus Therapeutic Use
  • Acronyms EVACEL; FFCD 1104-EVACEL-GTE

    • Most Recent Events

    • 27 Mar 2020 Status changed from active, no longer recruiting to completed.
    • 31 Oct 2019 Results (n=74) assessing efficacy and tolerability of Everolimus as treatment liver metastases from digestive endocrine tumors post to embolization or chemoembolization, published in the European Journal of Cancer.
    • 31 Oct 2019 Primary endpoint (Rate of hepatic progression free survival at 24 months) has not been met as per results published in the European Journal of Cancer.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top